‌

Q3 2018 Data Report

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Back to Publications

Global Landscape

892+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

476North America23Oceania1Africa142Asia15South America235Europe & Israel

Financings

Total Q3 2018 Global Financings

Total Global Financing

$2.8 Billion

 59%

Increase from Q3 2017

58.5%41.5%017.588.599.51010.511YTD 2018Full Year 2017

 40%

Increase year-over-year
$10.7B Raised YTD 2018

Gene & Gene-modified
Cell Therapy

$2.1 Billion

 35%

Increase from Q3 2017

56.9%43.1%015.866.26.46.66.877.27.47.67.8YTD 2018Full Year 2017

 34%

Increase year-over-year
$7.8B raised YTD 2018

Cell Therapy

$1.8 Billion

 73%

Increase from Q3 2017

60.0%40.0%013.844.24.44.64.855.25.45.65.866.2YTD 2018Full Year 2017

 32%

Increase year-over-year
$6.0B raised YTD 2018

Tissue Engineering

$1.5 Million

 91%

Decrease from Q3 2017

75.8%24.2%01200250300350400450500550600650700750800YTD 2018Full Year 2017

213%

Increase year-over-year
$786M raised YTD 2018

Total Global Financings by Type, by Year

11914088110226759622543961108814486355948746471250895IPOsFollow-OnsCorporatePartnershipsVenture CapitalPrivatePlacement /PIPES0$500m$1,000m$1,500m$2,000m$2,500m$3,000m$3,500m$4,000m$4,500m$5,000mYTD 2018Full Year 2017Full Year 2016
18869135391033Mergers &Acquisitions0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m$18,000m$20,000m$22,000m$24,000mYTD 2018Full Year 2017Full Year 2016

1003

Clinical trials underway
worldwide by the end of Q3 2018

PH. 1

330

PH. 2

580

PH. 3

93

32.9%57.8%9.3%050100150200250300350400450500550600Phase 1Phase 2Phase 3

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q3 2018

Gene Therapy
32.3%58.4%9.3%020406080100120140160180200220Phase IPhase IIPhase III
Gene-Modified
Cell Therapy
44.2%51.2%0020406080100120140160180Phase IPhase IIPhase III
Cell Therapy
21.6%66.8%11.7%020406080100120140160180200Phase IPhase IIPhase III
Tissue Engineering
24.4%46.3%29.3%010111213141516171819Phase IPhase IIPhase III

Clinical Trials by Indication: Q3 2018

Oncology
573
Cardiovascular
69
Central Nervous System
58
Musculoskeletal
58
Endocrine Metabolic & Genetic Disorders
43
Ophthalmology
37
Dermatology
33
Hematology
33
Immunology & Inflammation
31
Infectious Disease
24
Gastroenterology
13
Genitourinary Disorders
12
Respiratory
9
Lymphatic Diseases
3
Surgery
3
Ear Diseases
2
Geriatric Diseases
2

Report Infographics

View Full Report View Past Reports

Alliance for Regenerative Medicine

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

2-4 Schuman Roundabout
B-1040 Brussels
Belgium